Andrea DeCensi

Director

Champalimaud Foundation
Country flagPortugal

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

The 5th edition of the European Code Against Cancer (ECAC5) recommends sustainable, organised screening programmes for: (a) colorectal cancer using biennial quantitative faecal immunochemical test (FIT) for individuals aged 50–74 years. As an alternative strategy, once‐only endoscopy may be considered within the same age range; (b) breast cancer using biennial digital mammography for women aged 50–69 years. Implementing this strategy for women aged 45–49 years and 70–74 years can be considered. Other screening strategies or additional examinations could be considered for women with high mammographic density; (c) cervical cancer using human papillomavirus (HPV) screening at intervals no shorter than 5 years for women aged 30–65 years. It is recommended to adapt policies according to vaccination status and screening history; and (d) lung cancer using annual low‐dose computed tomography (LDCT) for individuals considered to be at increased risk of lung cancer based on age, history of smoking or validated risk models, with biennial screening as an alternative. Screening should incorporate smoking cessation interventions.

Year:

2026

Year:

2026

Year:

2026

Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7

Year:

2026

Cancer cells exhibit metabolic flexibility between anaerobic glycolysis and oxidative phosphorylation. Preclinical data showed that metformin, an oxidative phosphorylation inhibitor, combined with fasting-induced hypoglycemia led to activation of the PP2A–GSK3ß–Mcl1 axis and inhibition of tumor growth. A window-of-opportunity trial was designed to evaluate the effect of metformin and nightly fasting on proliferation in invasive breast cancer or ductal carcinoma in situ (DCIS). The primary endpoint is the pretreatment/posttreatment change of Ki67 in cancer tissue, and the co-primary endpoint is the difference in posttreatment Ki67 in cancer-adjacent DCIS or high-risk lesions. Participants with hormone receptor–positive invasive breast cancer or DCIS candidates to surgery are being accrued and randomized to either (i) fasting for ≥16 hours nightly, plus nutritional counseling and daily metformin with continuous glucose monitoring, or (ii) continuous glucose monitoring. The intervention lasts 4 to 6 weeks with gradual metformin ramp up to limit gastrointestinal disturbances. The safety of the combination was evaluated as a primary interim endpoint. The frequency of dose-limiting toxicity (≥G3 adverse events related to treatment) was assessed in the first 14 participants in the experimental arm. Most adverse events were of low grade (G1: 50; 90.9%) and unrelated to the treatment (G1: 26 unrelated; 52%). No one discontinued treatment because of toxicity, and no dose-limiting toxicities were observed, so the escalation phase of metformin was significantly shortened from 7 to 3 days. The results of this project will expand knowledge of this prevention approach and possibly provide the basis for large-scale primary prevention studies in at-risk women. Prevention Relevance: In a context of rising cancer drug costs, this research explores a low-cost treatment to optimize breast cancer preventive intervention. The approach is safe and based on repurposed drugs that could enhance prevention strategies for obesity- and insulin-related cancers, offering immediate applicability to a large-scale trial in women at risk.

Year:

2026

Cancer cells exhibit metabolic flexibility between anaerobic glycolysis and oxidative phosphorylation. Preclinical data showed that metformin, an oxidative phosphorylation inhibitor, combined with fasting-induced hypoglycemia led to activation of the PP2A–GSK3ß–Mcl1 axis and inhibition of tumor growth. A window-of-opportunity trial was designed to evaluate the effect of metformin and nightly fasting on proliferation in invasive breast cancer or ductal carcinoma in situ (DCIS). The primary endpoint is the pretreatment/posttreatment change of Ki67 in cancer tissue, and the co-primary endpoint is the difference in posttreatment Ki67 in cancer-adjacent DCIS or high-risk lesions. Participants with hormone receptor–positive invasive breast cancer or DCIS candidates to surgery are being accrued and randomized to either (i) fasting for ≥16 hours nightly, plus nutritional counseling and daily metformin with continuous glucose monitoring, or (ii) continuous glucose monitoring. The intervention lasts 4 to 6 weeks with gradual metformin ramp up to limit gastrointestinal disturbances. The safety of the combination was evaluated as a primary interim endpoint. The frequency of dose-limiting toxicity (≥G3 adverse events related to treatment) was assessed in the first 14 participants in the experimental arm. Most adverse events were of low grade (G1: 50; 90.9%) and unrelated to the treatment (G1: 26 unrelated; 52%). No one discontinued treatment because of toxicity, and no dose-limiting toxicities were observed, so the escalation phase of metformin was significantly shortened from 7 to 3 days. The results of this project will expand knowledge of this prevention approach and possibly provide the basis for large-scale primary prevention studies in at-risk women. Prevention Relevance: In a context of rising cancer drug costs, this research explores a low-cost treatment to optimize breast cancer preventive intervention. The approach is safe and based on repurposed drugs that could enhance prevention strategies for obesity- and insulin-related cancers, offering immediate applicability to a large-scale trial in women at risk.

Year:

2025

Purpose: Low-dose tamoxifen 5 mg/day (babytam) for 3 years can decrease the incidence of new breast cancer events in women with breast intraepithelial neoplasia by 42% with limited toxicity, which provides a new treatment option for these disorders. However, predictive biomarkers of babytam efficacy are lacking. We studied whether baseline levels of insulin-like growth factor-1 (IGF-I), IGF-binding protein-3 (IGFBP-3), estradiol, and sex hormone–binding globulin (SHBG) and their ratios predict babytam efficacy on breast cancer events in a preplanned secondary analysis. Patients and Methods: Within a 1:1 placebo-controlled, multicenter randomized trial of babytam or placebo administered for 3 years after surgery in women with hormone-sensitive or unknown breast intraepithelial neoplasia, including atypical ductal hyperplasia and lobular or ductal carcinoma in situ , 406 of 500 participants consented to blood sampling at baseline and at 1 and 3 years. Serum IGF-I, IGFBP-3, estradiol, and SHBG levels and their ratios were measured using chemiluminescent immunoassays. Biomarker changes were estimated using mixed-effects models, and incidence rate ratios were calculated after 10 years of follow-up with Poisson regression. Subgroup analyses were performed using an interaction test and subpopulation treatment effect pattern plot. Results: Baseline levels of IGFBP-3 in the three top quartiles (≥3.44 µg/mL), but not in the lower quartile, predicted greater babytam efficacy compared with placebo ( P interaction = 0.006). Baseline IGF-I, estradiol, or SHBG levels were not predictive of babytam efficacy, whereas the IGF-I/IGFBP-3 ratio was borderline significant ( P interaction = 0.067). Conclusions: High baseline levels of IGFBP-3 (≥3.44 µg/mL) predicted babytam efficacy and may help differentiate which women benefit most from this treatment.

Year:

2025

Background Breast Cancer (BC) prevention strategies range from lifestyle changes such as increasing physical activity and reducing body weight to preventive drugs like tamoxifen, known to reduce BC incidence in high-risk women. Sex Hormone Binding Globulin (SHBG) is related to BC risk due to its ability to bind circulating estradiol at high affinity and to regulate estradiol action. A study protocol is presented based on the assessment of the effect of different interventions such as tamoxifen at 10 mg every other day (LDT), intermittent caloric restriction (ICR) two days per week, lifestyle intervention (LI, step counter use) and their combination on the modulation of SHBG and several other biomarkers associated to BC. Methods A randomized phase II biomarker study will be conducted in 4 Italian centers. Unaffected women aged between 18 and 70 years, carriers of a germline pathogenetic variant ( BRCA1 , BRCA2 , PALB2 , or other moderate penetrance genes), or with a >5% BC risk at 10 years (according to the Tyrer-Cuzick or the Breast Cancer Surveillance Consortium Risk models) or with a previous diagnosis of intraepithelial neoplasia will be eligible. A total of 200 participants will be randomized to one of the four arms: LDT; LDT + ICR; LI; LI + ICR. Interventions will span six months, with baseline and follow-up clinic visits and interim phone calls. Discussion The aim of the study is to verify whether LDT increases circulating SHBG more than LI with or without ICR after 6 months. Secondary objectives include assessing HOMA-index, inflammatory markers, adiponectin/leptin ratio, quality of life (QoL), safety, toxicity, mammographic density, and changes in microbiome composition across groups. The study’s innovation lies in its inclusion of diverse BC risk categories and combination of pharmaceutical and behavioral interventions, potentially enhancing intervention efficacy while balancing tamoxifen’s side effects on QoL, especially menopausal symptoms. Trial registration EuCT number:2023-503994-39-00; Clinical trials.gov NCT06033092 .

Year:

2024

Obesity is a risk factor for postmenopausal breast cancer (BC), and evidence suggests a role for adiponectin in the relationship between obesity and BC. We investigated whether adiponectin or other biomarkers mediate the effect of body mass index (BMI) on postmenopausal BC risk in a cohort study nested in the IBIS-II Prevention Trial. We measured adiponectin, leptin, IGF-I, IGFBP-1, high-sensitivity C-reactive protein, glycemia, insulin, HOMA-IR index, and SHBG in baseline and 12-month serum samples from 123 cases and 302 matched controls in the placebo arm of the IBIS-II Prevention trial. We conducted the main mediation analysis considering baseline BMI as an exposure and the 12-month adiponectin increase as a mediator after adjustment for the Tyrer–Cuzick score and the lipid-lowering medications/supplements use. In the multivariable Cox model, both the 12-month adiponectin increase (HR, 0.60; 95%CI, 0.36–1.00) and BMI were associated with BC risk (HR, 1.05; 95%CI, 1.00–1.09), with a 40% reduction in women with a 12-month increase in adiponectin. A significantly higher cumulative hazard of BC events was observed in obese women (BMI > 30) with decreased adiponectin (p = 0.0087). No mediating effect of the adiponectin increase on the total effect of BMI on BC risk was observed (natural indirect effect: HR, 1.00; 95%CI, 0.98–1.02). Raising adiponectin levels might be an attractive target for postmenopausal BC prevention.

Year:

2024

Background/Objectives: Our previous study of 291 cancer patients, we showed that 20% did not respond to two doses of COVID-19 vaccine administered six weeks apart. Methods: Here, we investigated if psychological factors (distress, anxiety, and depressive symptoms) affected antibody response and markers of vaccine activation (D-dimer) after 6 months from initial vaccination. Results: Overall, 31 subjects (14.2%) had no antibody response at 6 months. Our analysis revealed significant predictors of vaccine failure, including the stage of metastatic disease and high-stress levels (OR = 2.46, 95% CI, 1.05–5.77, p = 0.04). Notably, nonresponders showed twice the prevalence of distress than responders (21% vs. 10%, p = 0.04). Longitudinal measurements of IgG levels indicated that participants with high depressive symptoms at baseline maintained lower antibody levels over six months (p = 0.003). In addition, women with high anxiety showed reduced levels of D-dimer at 6 months (p = 0.03). These data also showed that smokers and former smokers had significantly lower antibody levels than their nonsmoking counterparts (p = 0.0004). At baseline, the high discomfort rate (≥5) was 34.4% in women and 23.8% in men; only men experienced an increase in median discomfort during the observation period. Moreover, a higher educational level was related to increased distress among women (p = 0.046). Conclusions: These findings underscore a critical association between elevated psychological distress and reduced immune responses to the COVID-19 vaccine, emphasizing the urgent need for targeted psychological and behavioral support within this vulnerable population.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (34)

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

-

ITALY
View details

Valentina Guarneri

Associate Professor

University of Padova

ITALY
View details

Maurizio Simmaco

Full Professor Molecular Biology - Director Diparmet Diagnostic sciences

Sapienza University of Rome

ITALY
View details

Javier Bracchiglione Pérez

Institut de Recerca Sant Pau

SPAIN
View details

Matteo Lazzeroni

European Institute of Oncology

ITALY
View details

Umberto Malapelle

-

ITALY
View details

Edoardo Crimini

Medical Oncologist

European Institute of Oncology

ITALY
View details

Francisco Oliveira

Researcher

Champalimaud Foundation

PORTUGAL
View details

Marco Musso

Ricercatore sanitario

Ospedale Policlinico San Martino

ITALY
View details

Giuseppe Tonini

Full Professor of Medical Oncology

Campus Bio Medico University Hospital

ITALY
View details

Paolo Veronesi

Docenti

University of Milan

ITALY
View details

Anssi Auvinen

University of Tampere

FINLAND
View details

Laura Paleari

-

ITALY
View details

Giuseppe Giannini

Head, Unit of Advanced Molecular Diagnostic in Oncology

Sapienza University

ITALY
View details

David R Baldwin

University of Nottingham

UNITED KINGDOM
View details

Lucia Del Mastro

dirigente medico

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro

ITALY
View details

Hajo Zeeb

Head

Leibniz Institute for Prevention Research and Epidemiology - BIPS

GERMANY
View details

Aliana Guerrieri Gonzaga

Istituto Europeo di Oncologia

ITALY
View details

Giancarlo Pruneri

University of Milan

ITALY
View details

Eduardo Vilar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Giuseppe Curigliano

European Institute of Oncology

ITALY
View details

Sara Gandini

Group Leader T, PhD

European Institute of Oncology

ITALY
View details

Lidia Strigari

Head of Department

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Alberto Zambelli

Associate Professor

University of Milano-Bicocca

ITALY
View details

Paolo Marchetti

Sapienza University of Rome

ITALY
View details

SIMONA PISEGNA

Sapienza University of Rome

ITALY
View details

Matteo Lambertini

University of Genova

ITALY
View details

Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

ITALY
View details

Susana Vinga

Associate Professor

Universidade de Lisboa Instituto Superior Técnico

PORTUGAL
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

PIERFRANCO CONTE

Professore di 1^ fascia

University of Padova

ITALY
View details

Saverio Minucci

European Institute of Oncology

ITALY
View details

Chiara Cremolini

University Hospital of Pisa

ITALY
View details

Laura Cortesi

University of Modena and Reggio Emilia

ITALY
View details